Related Experiment Video

Updated: Mar 1, 2026

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

12.4K

Current options to manage Waldenström's macroglobulinemia

Giulia Benevolo1, Maura Nicolosi1, Elisa Santambrogio1

  • 1a Division of Hematology , AOU Città della Salute e della Scienza , Torino , Italy.

Expert Review of Hematology
|June 9, 2017
PubMed
Abstract

Insights

Waldenström's macroglobulinemia (WM) treatment involves standard therapies like RCD and BRD, alongside new drugs such as ibrutinib. While effective, WM remains incurable, necessitating ongoing clinical trial participation.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Waldenström's macroglobulinemia (WM) is a rare, incurable B-cell lymphoma.
  • Current standard of care lacks consensus, with various agents used.
  • Median survival for symptomatic patients is 5-10 years.

Purpose of the Study:

  • To review standard therapies for WM.
  • To discuss novel therapeutic agents under investigation for WM.
  • To provide expert commentary on current and emerging WM treatments.

Main Methods:

  • Review of existing literature on WM therapies.
  • Analysis of clinical data for standard and investigational drugs.
  • Expert opinion on treatment efficacy and safety.

Main Results:

  • Rituximab/Cyclophosphamide/Dexamethasone (RCD) is effective and safe for first-line WM treatment.
  • Bendamustine/Rituximab (BR) or Bortezomib/Rituximab/Dexamethasone (BRD) offer durable responses.
  • Ibrutinib is approved for primary and relapsed therapy; Carfilzomib-based therapy is an emerging option.

Conclusions:

  • WM remains an incurable disease despite encouraging treatment results.
  • New therapeutic options are continuously needed.
  • Encouraging patient participation in clinical trials is crucial for advancing WM treatment.
Keywords:
Bruton’s tyrosine kinase inhibitorsWaldenström’s macroglobulinemiamonoclonal antibodynew drugstreatment options

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
266
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
399
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
281
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
422